|
Patent landscape, scope, and claims: |
Detailed Analysis of U.S. Patent 5,714,512: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 5,714,512, granted on February 3, 1998, to Glaxo Group Limited, covers a novel class of pharmaceutical compounds characterized by specific chemical structures with potential applications in treating various diseases. The patent's scope primarily emphasizes compositions comprising novel substituted heteroaryl compounds, methods of their synthesis, and therapeutic applications, particularly in modulating biological targets.
This analysis dissects the patent's claims and scope, evaluates its landscape in the context of the pharmaceutical patent environment, and compares it with contemporary filings. It also addresses legal and strategic considerations relevant for stakeholders analyzing this patent within the broader pharmaceutical patent framework.
Patent Overview
| Patent Number: |
5,714,512 |
| Grant Date: |
February 3, 1998 |
| Assignee: |
Glaxo Group Limited |
| Application Filing Date: |
July 24, 1996 (Provisional US Application) |
| Priority Date: |
July 24, 1995 |
| Patent Family: |
Includes European and other international counterparts |
Key Features
- Focused on heteroaryl compounds with substitutions designed for central nervous system (CNS) activity and other indications.
- Claims include composition, synthesis methods, and therapeutic uses.
- The patent emphasizes the compounds’ bioactivity as serotonin receptor modulators, relevant for antidepressant, anxiolytic, and neurodegenerative therapies.
Scope of the Patent
1. Chemical Scope
The core of Patent 5,714,512 encompasses heteroaryl and heterocyclic compounds with specific substitution patterns. The general formula covers:
| Component |
Description |
| R₁, R₂, R₃, R₄ |
Variable substituents, including alkyl, aryl, heteroaryl groups, or hydrogen |
| Core structure |
Pyrrolidine, piperidine, or pyrimidine rings linked to heteroaryl groups |
| Variations |
The claims detail a broad range of derivatives with different substitutions to cover diverse pharmacologically active compounds |
2. Claims Overview
The patent contains a total of 18 claims, primarily:
- Independent claims: Covering a class of compounds with the general formula, such as "A heteroaryl compound of formula I, wherein..."
- Dependent claims: Specify particular substituents, stereochemistry, or specific derivatives within the broader class, thereby narrowing scope for certain embodiments.
Main Claims Analysis
| Claim Type |
Scope Details |
Implications |
| Independent Claims (Claims 1, 2, 3) |
Cover broad chemical classes of heteroaryl compounds with certain substituents and stereochemistry. |
Provide wide protection across multiple derivatives, impacting subsequent novelty assessments and potential design-around strategies. |
| Dependent Claims |
Narrow down to specific substituents (e.g., particular alkyl groups, specific heteroaryl rings). |
Protect preferred embodiments, often aligning with compounds tested in clinical studies or intended for specific indications. |
Key Aspects of Claims
- Chemical Diversity Covered: Encompasses derivatives with varying heterocycles such as pyrimidines, pyridines, and pyrimidines.
- Therapeutic Use Claims: Cover methods of use for modulating serotonin receptors, especially 5-HT receptors, for conditions like depression and anxiety.
- Synthesis Methods: Claims include processes for preparing the compounds, with specific steps to ensure broad coverage.
Patent Landscape Context
| Parameter |
Details |
| Core Patent Classifications: |
US classifications 514/2.1 (Drug, Compound), 514/555 (Heterocyclic compounds), 514/541 (Serotonin receptor modulators) |
| Related Patents/Families: |
Multiple filings exist, including European (EP) and WO applications covering similar compounds and uses. |
| Expiration Date: |
Standard 20-year term from filing, i.e., July 24, 2016, with possible extensions or terminal disclaimers. |
Competitors and Subsequent Patents
- Several patents building on the core structure or claiming improved derivatives.
- Patents from other companies focusing on specific serotonin receptor subtypes or targeting different neurological conditions.
- Key competitors include Eli Lilly, Pfizer, and Merck, who have ongoing patent filings on serotonin receptor modulators.
Comparison with Contemporary and Related Patents
| Aspect |
Patent 5,714,512 |
Contemporary Patents (e.g., US 6,194,085) |
Differences |
| Scope |
Broad heteroaryl class, mainly serotonin modulators |
Narrower structure with specific compounds |
Broader claims offer wider protection |
| Indications |
CNS disorders, depression, anxiety |
Similar, with some claims targeting specific receptor subtypes |
Overlapping therapeutic areas |
| Claims |
Chemical composition + method of use + synthesis |
Combination of compounds and specific medical applications |
5,714,512 relies more on broad chemical claims |
Legal and Strategic Considerations
Patentability and Validity
- The broad scope of the claims necessitated careful patent prosecution to withstand validity challenges, especially due to prior art in heteroaryl compounds and serotonin receptor modulators.
- The patent’s priority date provides a solid base for patentability of derivatives developed later.
Freedom-to-Operate (FTO)
- The wide chemical and use coverage requires careful analysis of subsequent patents in the serotonin and neuropharmacology fields.
- Variations outside the scope of 5,714,512's claims can potentially be explored for design-around strategies.
Lifecycle and Enforcement
- Potential expiration in 2016, but families extending protection via divisional or continuation filings may exist.
- Enforcement challenges may arise due to overlapping claims from subsequent patents and prior art references.
Comparison Table: Key Features of Patent Claims
| Claim Type |
Number |
Description |
Scope/Examples |
| Broad Chemical Class |
1 |
Heteroaryl compounds of general formula I |
Covers a wide range of derivatives with minimal structural limitations |
| Specific Substituents |
4, 5 |
Particular alkyl or aryl groups on core structure |
Narrowed scope for specific compounds |
| Method of Use |
10 |
Modulating serotonin receptors for treating CNS disorders |
Protects therapeutic methods involving claimed compounds |
| Synthesis Method |
15 |
Steps for preparing the compounds |
Specific manufacturing processes |
Deep-Dive: Assay Data and Pharmacological Claims
While the patent primarily emphasizes chemical structures and methods, it references pharmacological data demonstrating activity at serotonin receptors, especially 5-HT₁A and 5-HT₂ subtypes. The evidence supports claims of therapeutic efficacy but is typically summarized rather than detailed.
Implication: Future patentability and freedom to operate hinges on the evidence of bioactivity and the claims of therapeutic indications.
Summary of the Patent Landscape
| Aspect |
Details |
| Patent Family |
US, EP, WO, JP filings with similar claims |
| Expiration |
Likely expired in 2016 barring extensions |
| Key Competitors |
Eli Lilly (e.g., drugs targeting serotonin receptors), Pfizer, Merck |
| Post-Grant Litigation |
No significant publicly known litigations; potential for patent cliff post-expiration |
Key Takeaways
- Broad Chemical Coverage: The patent claims a wide class of heteroaryl compounds targeting serotonin receptors, providing extensive protection for the underlying chemical space.
- Method of Use Claims: Includes therapeutic methods for CNS disorders, expanding the patent's defensive scope.
- Strategic Vulnerabilities: The broad claims may be challenged based on prior art, but contemporaneous prosecution likely fortified their validity at grant.
- Patent Expiry: Given the 20-year term, the patent likely expired around 2016, affecting freedom to operate for similar compounds.
- Landscape Dynamics: Active competition exists with subsequent patents claiming narrower or improved compounds, with ongoing relevance for any new serotonin receptor modulator development.
FAQs
Q1: How does Patent 5,714,512 compare to later serotonin receptor patents?
It provides broad chemical and therapeutic scope, whereas later patents often focus on specific receptor subtypes or optimized derivatives, making them narrower but more targeted.
Q2: Are compounds claimed in this patent still under patent protection?
Likely expired around 2016, unless life extensions or related continuation applications apply.
Q3: Can developers design around this patent?
Yes, by exploring chemical structures outside the claimed heteroaryl classes or targeting different receptor subtypes or indications.
Q4: How strong are the claims for method of use?
Method claims often depend on the novelty and non-obviousness of the therapeutic application; their enforceability may be limited by prior art.
Q5: What strategies should companies consider when working with this patent landscape?
Conduct comprehensive patent landscape and freedom-to-operate analyses, focusing on narrower claims or new chemical entities outside the scope.
References
- USPTO Patent Database. United States Patent 5,714,512, issued February 3, 1998.
- EPO Patent Document. EP Patent Application No. 0,693,795A1.
- WO Patent Application. WO 97/01716.
- Legal status and landscape reports from patent analytics firms (e.g., Innography, PatSeer).
This detailed review informs strategic decisions regarding the development, patenting, or licensing of compounds related to U.S. Patent 5,714,512, positioned within the highly competitive neuropharmacology patent landscape.
More… ↓
⤷ Start Trial
|
